Brexogen Inc.

2 clinical trials · Sponsor

Record	Firm	Date
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Repeated-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis (NCT06055374)	Brexogen Inc.	2024-05-01

Every clearance here is in the API, with alerts when new ones post.